A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to less than 18 years of age) With Inadequately Controlled Partial-onset Seizures

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to less than 18 years of age) With Inadequately Controlled Partial-onset Seizures

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 28 Apr 2017 Results of exploratory analysis assessing the potential of perampanel as monotherapy using data from two prospective open-label extension studies (NCT00735397 and NCT01161524) and a retrospective study (NCT02736162), presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 13 Apr 2017 According to an Eisai Inc media release, results assessing perampanel as monotherapy from studies (307, 235 and 504) will be presented at the American Academy of Neurology (AAN) Annual Meeting.
    • 06 Dec 2016 Results of pooled post-hoc analysis of safety and efficacy of perampanel in adolescent patients from six studies including this study presented at the 70th Annual Meeting of the American Epilepsy Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top